

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

7

**Complete if Known**

Application Number	10/520,897
Filing Date	January 11, 2005
First Named Inventor	Sverre SONDBØ
Art Unit	1621
Examiner Name	Deborah D. Carr
Attorney Docket Number	10260.0007-00000

**U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS**

Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1.	US-2,985,589	05-23-1961	Broughton et al.	
	2.	US-3,158,541	11-24-1964	Sutherland	
	3.	US-3,696,107	10-03-1972	Neuzil	
	4.	US-3,706,812	12-19-1972	de Rosset et al.	
	5.	US-3,761,533	09-25-1973	Otani et al.	
	6.	US-4,061,556	12-06-1977	Reis et al.	
	7.	US-4,124,528	11-07-1978	Modell	
	8.	US-4,147,624	04-03-1979	Modell	
	9.	US-4,156,688	05-29-1979	Zosel	
	10.	US-4,352,746	10-05-1982	Bracco et al.	
	11.	US-4,377,525	03-22-1983	D'Alelio, deceased et al.	
	12.	US-4,377,526	03-22-1983	Fujita et al.	
	13.	US-4,415,554	11-15-1983	Horrobin	
	14.	US-4,526,902	07-02-1985	Rubin	
	15.	US-4,564,475	01-14-1986	Masaichiro	
	16.	US-4,615,839	10-07-1986	Seto et al.	
	17.	US-4,675,132	06-23-1987	Stout et al.	
	18.	US-4,681,896	07-21-1987	Horrobin	
	19.	US-4,692,280	09-08-1987	Spinelli et al.	
	20.	US-4,758,592	07-19-1988	Horrobin et al.	
	21.	US-4,792,418	12-20-1988	Rubin et al.	
	22.	US-4,956,286	09-11-1990	Macrae	
	23.	US-4,956,287	09-11-1990	Suzuki et al.	
	24.	US-5,013,443	05-07-1991	Higashidate et al.	
	25.	US-5,130,061	07-14-1992	Cornieri et al.	
	26.	US-5,130,449	07-14-1992	Lagarde et al.	
	27.	US-5,316,927	05-31-1994	Zaks et al.	
	28.	US-5,480,787	01-02-1996	Negishi et al.	
	29.	US-5,502,077	03-26-1996	Breivik et al.	
	30.	US-5,656,667	08-12-1997	Breivik et al.	
	31.	US-5,698,594	12-16-1997	Breivik et al.	
	32.	US-5,719,302	02-17-1998	Perrut et al.	
	33.	US-6,204,401 B1	03-20-2001	Perrut et al.	
	34.	US-6,277,405 B1	08-21-2001	Stamm et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.D.C

IDS Form PTO/SB/08: Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/520,897
				Filing Date	January 11, 2005
				First Named Inventor	Sverre SONDBØ
				Art Unit	1621
				Examiner Name	Deborah D. Carr
Sheet	2	of	7	Attorney Docket Number	10260.0007-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
	35.	US-6,518,049 B1	02-11-2003	Haraldsson et al.	
	36.	US-2002/0077361 A1	06-20-2002	Peet et al.	
	37.	US-2003/0077342 A1	04-24-2003	Maffetone	
	38.	US-2003/0212138 A1	11-13-2003	Obukowicz	
	39.	US-2005/0171200 A1	08-04-2005	Calder et al.	
	40.	US-2005/0256326 A1	11-17-2005	Breivik et al.	
	41.	US-2006/0148047 A1	07-06-2006	Haraldsson et al.	
	42.	US-2006/0166935 A1	07-27-2006	Bryhn	
	43.	US-2006/0211762 A1	09-21-2006	Rongen et al.	
	44.	US-2007/0036862 A1	02-15-2007	Rongen et al.	
	45.	US-2008/0234375 A1	09-25-2008	Breivik et al.	

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	46.	AT 347551	01-10-1979	Studienge-sellschaft Kohle mbH		English counterpart
	47.	AT 328597	03-25-1976	Studienge-sellschaft Kohle mbH		Translation
	48.	CL 42559	10-16-1998	Cabby Business Inc.		Translation
	49.	DE 3 839 017 A1	05-23-1990	Henkel KGaA		Abstract
	50.	DE 2 332 038 C3	01-24-1974	Studiengesellschaft Kohle mbH		Abstract
	51.	EP 0 442 184 A1	08-21-1991	Campbell Soup Company		
	52.	EP 0 292 846 B1	11-30-1988	Star Oil Ltd.		
	53.	EP 0 283 140 B1	09-21-1988	Efamol Holdings		
	54.	EP 0 175 468 A2	03-26-1986	Sentrachem Ltd.		
	55.	EP 1 419 780 A1	05-19-2004	Martek Biosciences Corp.		
	56.	FR 2 694 208 A1	02-04-1994	Separex		Abstract
	57.	FR 2 686 028 A1	07-16-1993	Achenbach Buschhütten GmbH		Abstract
	58.	FR 2 690 630 A1	11-05-1993	Separex S.A.		Abstract
	59.	FR 2 651 148 A1	03-01-1991	Inst. Français du Petrole		Abstract
	60.	FR 2 651 149 A1	03-01-1991	Inst. Français du Petrole		Abstract
	61.	FR 2 527 934	12-09-1983	Elf Aquitaine		Abstract
	62.	FR 2 103 302	04-07-1972	Toray Ind., Inc.		Abstract
	63.	GB 2 197 199 A	05-18-1988	Efamed Pty. Ltd.		
	64.	GB 2 148 713 A	06-05-1985	Century Laboratories Inc.		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.D.C

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>		
				Application Number		10/520,897
				Filing Date		January 11, 2005
				First Named Inventor		Sverre SONDBØ
				Art Unit		1621
				Examiner Name		Deborah D. Carr
Sheet	3	of	7	Attorney Docket Number		10260.0007-00000

FOREIGN PATENT DOCUMENTS						
	65.	GB 1 604 554	12-09-1981	Wellcome Foundation Ltd.		
	66.	GB 2 033 745 A	05-29-1980	Wellcome Foundation Ltd.		
	67.	GB 2 221 843 A	02-21-1990	Norsk Hydro A.S.		
	68.	GB 2 218 984 A	11-29-1989	Renafield Ltd.		
	69.	JP 39-05538	07-08-2003	Pronova Biocare AS		Abstract
	70.	JP 9-510091	10-14-1997	Norsk Hydro AS		Abstract
	71.	JP 60-33088	02-20-1985	Nippon Suisan Kaisha Ltd.		Abstract
	72.	JP 1-252294	10-06-1989	Nippon Oil & Fats Co. Ltd.		Abstract
	73.	JP 61-192797	08-27-1986	Nippon Oils & Fats K.K.		Abstract
	74.	JP 59-14793	01-25-1984	Nippon Oil & Fats Co. Ltd.		Abstract
	75.	JP 6-116585	04-26-1994	Kanebuchi Kagaku Kogyo K.K.		Abstract
	76.	JP 6-293895	10-21-1994	Shokuhin Sangyo High		Abstract
	77.	JP 2-25447	01-26-1990	Nippon Oil & Fats co. Ltd.		Abstract
	78.	WO 1986/03781	07-03-1986	Sintef		
	79.	WO 1987/03899 A1	07-02-1987	Norsk Hydro A.S.		
	80.	WO 1987/02247 A1	04-23-1987	Baxter Travenol Laboratories, Inc.		
	81.	WO 1988/08444 A1	11-03-1988	MTA Szegedi Biológiai Központja		
	82.	WO 1989/11521 A1	11-30-1989	Staroil Ltd.		
	83.	WO 1990/13656	11-15-1990	Enzytech, Inc.		
	84.	WO 1991/16443	10-31-1991	Novo Nordisk A.S.		
	85.	WO 1998/18952 A1	05-07-1998	Nippon Suisan Kaisha, Ltd.		Abstract

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
	86.	ABBATE, R. et al. "n-3 PUFA supplementation, monocyte PCA expression and interleukin-6 production," <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> (1996), 54(6), 439-444.	
	87.	ABE, Y. et al. "Soluble Cell Adhesion Molecules in Hypertriglyceridemia and Potential Significance on Monocyte Adhesion," <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> (1998), 18(5), 723-731.	
	88.	ABHYANKAR, B. "Further reduction in mortality following myocardial infarction," <i>J. Hospital Medicine</i> (2002), 63(10), 610-614.	
	89.	ACKMAN, R.G. "Oils and Fats Group International Lecture: The year of the fish oils," <i>Chemistry and Industry</i> (1988) 139-145.	
	90.	ADACHI, S. et al. "Acidolysis of Sardine Oil by Lipase to Concentrate Eicosapentaenoic and Docosahexaenoic Acids in Glycerides," <i>J. Ferment. Bioeng.</i> (1993), 75(4), 259-264.	
	91.	BIMBO, A. P. "Processing of Fish Oils" in <i>Fish Oils in Nutrition</i> , M.E. Stansby, Ed. (1990) 181-225.	
	92.	BLONK, "Dose-response effects of fish-oil supplementation in healthy volunteers," <i>Am. J. Clin. Nutr.</i> (1990), 52, 120-127.	
	93.	BØNAA, K. H. et al. "Effect of Eicosapentaenoic and Docosahexaenoic Acids on Blood Pressure in Hypertension," <i>New England J. of Medicine</i> (1990), 322, 795-801.	
	94.	BOUSQUET, O. et al. "Counter-current chromatographic separation of polyunsaturated fatty acids," <i>J. Chromatography A</i> (1995), 704, 211-216.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.D.C

IDS Form PTO/SB/08: Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/520,897
		Filing Date	January 11, 2005
		First Named Inventor	Sverre SONDBØ
		Art Unit	1621
		Examiner Name	Deborah D. Carr
Sheet	4	of	7
		Attorney Docket Number	10260.0007-00000

NONPATENT LITERATURE DOCUMENTS			
	95.	BRAUNWALD et al. "Harrison's Principles of Medicine," 11 <sup>th</sup> ed. (McGraw-Hill, New York, 1985) p. 1204.	
	96.	BREIVIK, H. et al. "Preparation of Highly Purified Concentrates of Eicosapentaenoic Acid and Docosahexaenoic Acid," <i>J. Am. Oil. Chem. Soc.</i> (1997), 74(11), 1425-1429.	
	97.	BREIVIK, H. "Production and Quality Control of n-3 Fatty Acids," <i>Clinical Pharmacology</i> (1992), 5, 25-39.	
	98.	BRYHN, M. et al. "The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters," <i>Prostaglandins, leukotrienes and Essential Fatty Acids</i> (2006), 75, 19-24.	
	99.	CAPLUS English Abstract for DE BERNARDI et al. <i>Acta Toxicol. Ther.</i> (1987), 8(3), 339-352; Accession No. 1988:604885.	
	100.	CALABRESI, L. et al. "Omacor in familial combined hyperlipidemia : Effects on lipids and low density lipoprotein subclasses," <i>Atherosclerosis</i> (2000), 148(2), 387-396.	
	101.	CHAN, D. C. et al "Regulatory Effects of HMG CoA Reductase Inhibitor and Fish Oils on Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Male Subjects With Dyslipidemia," <i>Diabetes</i> (2002), 51, 2377-2386.	
	102.	CVENGROS, J. "Physical Refining of Edible Oils," <i>J. Am. Oil Chem. Soc.</i> (1995), 72(10), 1193-1196.	
	103.	DATABASE WPI: Week 199022, Derwent Publications Ltd., DE 3839017.	
	104.	DATABASE WPI: Week 198001, Derwent Publications Ltd., DE 2332038.	
	105.	DATABASE WPI: Week 197402, Derwent Publications Ltd., DE 2332038.	
	106.	DATABASE WPI: Week 199346, Derwent Publications Ltd., FR 2694208.	
	107.	DATABASE WPI: Week 199329, Derwent Publications Ltd., FR 2686028.	
	108.	DATABASE WPI: Week 199110, Derwent Publications Ltd., FR 2651148.	
	109.	DATABASE WPI: Week 199110, Derwent Publications Ltd., FR 2651149.	
	110.	DATABASE WPI: Week 198403, Derwent Publications Ltd., FR 2527934.	
	111.	DATABASE WPI: Week 197228, Derwent Publications Ltd., FR 2103302.	
	112.	DATABASE WPI: Week 198514, Derwent Publications Ltd., JP 60033088.	
	113.	DATABASE WPI: Week 198641, Derwent Publications Ltd., JP 61192797.	
	114.	DATABASE WPI: Week 198410, Derwent Publications Ltd., JP 59014793.	
	115.	DATABASE WPI: Week 198946, Derwent Publications Ltd., JP 1252294.	
	116.	DATABASE WPI: Week 200417, Derwent Publications Ltd., JP 3905538.	
	117.	DATABASE WPI: Week 199542, Derwent Publications Ltd., JP 9510091.	
	118.	DATABASE WPI: Week 199502, Derwent Publications Ltd., JP 6-293895.	
	119.	DATABASE WPI: Week 199421, Derwent Publications Ltd., JP 6116585.	
	120.	DATABASE WPI: Week 199010, Derwent Publications Ltd., JP 2025447.	
	121.	DE BERNARDI et al. "Study of Perinatal and Postnatal Effects in Rats After Oral Administration with a New Drug Containing Eicosapentaenoic Acid and Docosahexaenoic Acid at 85%," <i>Acta Toxicol. Ther.</i> (1987), 8(3), 339-352.	Abstract
	122.	Derwent abstract of ZA 198905758.	
	123.	DIEP, Q. N. et al "Docosahexaenoic Acid, a Peroxisome Proliferator-Activated Receptor- $\alpha$ Ligand, Induces Apoptosis in Vascular Smooth Muscle Cells by Stimulation of p38 Mitogen-Activated Protein Kinase," <i>Hypertension</i> (2000), 36, 851-855.	
	124.	DONADIO, J. V. "Use of fish oil to treat patients with immunoglobulin A nephropathy" <i>Am. J. Clin. Nutr.</i> (2000), 71(Suppl), 373S-375S.	
	125.	DONADIO, J. V. et al. "A Randomized Trial of High-Dose Compared with Low-Dose Omega-3 Fatty Acids in Severe IgA Nephropathy," <i>J. Am. Soc. Nephrol.</i> (2001), 12(4), 791-799.	
	126.	DURRINGTON, P. N. et al. "An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia," <i>Heart</i> (2001), 85(5), 544-548.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.D.C

IDS Form PTO/SB/08: Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/520,897	
			Filing Date	January 11, 2005	
			First Named Inventor	Sverre SONDBØ	
			Art Unit	1621	
			Examiner Name	Deborah D. Carr	
Sheet	5	of	7	Attorney Docket Number	10260.0007-00000

NONPATENT LITERATURE DOCUMENTS			
	127.	English translation of AT 328597.	
	128.	English translation of CL 42559.	
	129.	EPAX marketing information (7 pages).	
	130.	EPAX production information (6 pages).	
	131.	FRANZOSI, M. G. et al "Cost-Effectiveness Analysis of n-3 Polyunsaturated Fatty Acids (PUFA) after Myocardial Infarction," <i>Pharmacoeconomics</i> (2001), 19(4), 411-420.	
	132.	GAUGLITZ, E.J. et al. "Adsorptive Bleaching and Molecular Distillation of Menhaden Oil," <i>Journal of the American Oil Chemists Society</i> (1965), 42, 561-563.	
	133.	GISSI-PREVENZIONE INVESTIGATORS "Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial," <i>Lancet</i> (1999), 354, 447-455.	
	134.	HAMAZAKI, T. et al. "Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients," <i>Kidney International</i> (1984), 26(1), 81-84.	
	135.	HARALDSSON, G. G. et al. "Studies on the Positional Specificity of Lipase from <i>Mucor miehei</i> During Interesterification Reactions of Cod Liver Oil with n-3 Polyunsaturated Fatty Acid and Ethyl Ester Concentrations," <i>Acta Chemica Scandinavica</i> (1991), 45, 723-730.	
	136.	HARALDSSON, G. G. et al. "Separation of Eicosapentaenoic Acid and Docosahexaenoic Acid in Fish Oil by Kinetic Resolution Using Lipase," <i>J. Am. Oil Chem. Soc.</i> (1998), 75(11), 1551-1556.	
	137.	HARALDSSON, G. G. et al. "The Preparation of Concentrates of Eicosapentaenoic Acid and Docosahexaenoic Acids by Lipase-Catalyzed Transesterification of Fish Oil with Ethanol," <i>J. Am. Oil. Chem. Soc.</i> (1997), 74(11), 1419-1424.	
	138.	HARRIS, W. S. et al. "Safety and efficacy of Omacor in severe hypertriglyceridemia," <i>Journal of Cardiovascular Risk</i> (1997), 4(5-6), 385-391.	
	139.	HELLSTRÖM, "Some Foreign Recommendations on the Treatment of Hyper-lipidaemias," in <i>Treatment of Hyperlipidemia</i> , National Board of Health and Welfare Drug Information Center, Sweden (1989) 131-137.	
	140.	HELLSTRÖM "Treatment of Hyperlipidemia: Opinions and recommendations from the group," in <i>Treatment of Hyperlipidemia</i> , National Board of Health and Welfare Drug Information Committee, Sweden (1989) 147-158.	
	141.	HOGG, R. J. et al. "Advances in Treatment: Immunoglobulin A Nephropathy," <i>Seminars in Nephrology</i> (1996), 16(6) 511-516.	
	142.	HOSHINO, T. et al. "Selective Hydrolysis of Fish Oil By Lipase to concentrate N-3 Polyunsaturated Fatty Acids," <i>Agric. Biol. Chem.</i> (1990), 54(6), 1459-1467.	
	143.	Information from <a href="http://www.epax.com">http://www.epax.com</a> (6 pages).	
	144.	Information from <a href="http://www.omacor.com">http://www.omacor.com</a> (25 pages).	
	145.	Information from <a href="http://www.omacorr.com">http://www.omacorr.com</a> (45 pages).	
	146.	Japanese Litigation, Demand for Trial dated August 31, 2007.	
	147.	JOHANSEN, O. et al. "n-3 Fatty Acids Do Not Prevent Restenosis After Coronary Angioplasty: Results from the CART Study," <i>Journal of the American College of Cardiology</i> (1999), 33(6), 1619-1626.	
	148.	JULSHAMN, K. et al. "Removal of DDT and its metabolites from fish oils by molecular distillation," <i>Fiskeridirektoratets Skrifter Serie Teknologiske Undersøkelser</i> (1978), 5(15), 3-11.	
	149.	KANEMATSU et al "Studies on the behaviour of trace components in oils and fats during processing for edible use. I. Removal of organochlorine pesticides and polychlorinated biphenyls (PCB) from oils and fats," <i>J. of Japan. Oil Chemists' Society</i> (1976), 25(1), 38-41.	Abstract
	150.	KINSELLA et al. <i>Seafoods and Fish Oils in Human Health and Disease</i> (New York, Marcel Dekka Inc. 1987) pp. 7-9.	
	151.	KRIS-ETHERTON et al. "Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease," <i>Circulation</i> (2002), 106, 2747-2757.	
	152.	KUK, M. S. "Supercritical carbon dioxide extraction of cottonseed with co-solvents," <i>J. Am. Oil Chem. Soc.</i> (1994), 71(12), 1353-1356.	
	153.	LARSEN et al. "Biosynthesis of Alginate," <i>Int. Seaweed Symp.</i> 7 <sup>th</sup> (1971), 491-495.	
	154.	LIE, E. et al. "Esterification of polyunsaturated fatty acids with lipases from different sources," <i>International J. of Food Science and Technology</i> (1992), 27, 73-76.	
	155.	LIE, et al. "Fatty Acid Specificity of Candida cylindracea Lipase," <i>Feet, Seifen, Anstrichmittel</i> (1986), 88(9), 365-367.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.D.C

IDS Form PTO/SB/08: Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/520,897
		Filing Date	January 11, 2005
		First Named Inventor	Sverre SONDBØ
		Art Unit	1621
		Examiner Name	Deborah D. Carr
		Attorney Docket Number	10260.0007-00000
Sheet	6	of	7

NONPATENT LITERATURE DOCUMENTS			
156.	LIM, G. P. et al. "A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model," <i>J. Neuroscience</i> (2005), 25(12), 3032-3040.		
157.	Lovaza™ labeling information, Reliant Pharmaceuticals (revised June 2007, 2 pages).		
158.	Lovaza™ marketing information (2 pages).		
159.	LULEY, C. et al. "Bioavailability of Omega-3 Fatty Acids: Ethylester Preparation are Suitable as Triglyceride Preparations," <i>Nutrition Lances</i> (1990), 123-125.		
160.	LUNGERSHAUSEN, Y. K. et al. "Reduction of blood pressure and plasma triglycerides by omega-3 fatty acids in treated hypertensives," <i>Journal of Hypertension</i> (1994), 12(9), 1041-1045.		
161.	MARCHIOLI, R. et al "Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction," <i>Circulation</i> (2002), 105, 1897-1903.		
162.	MCNEILL, G. P. "Lipase-Catalyzed Enrichment of Long-Chain Polyunsaturated Fatty Acids," <i>JAOCS</i> (1996), 73(11), 1403-1407.		
163.	Merck Index, 11 <sup>th</sup> Ed. (Rahway, NJ. Merck and Co., 1989) p. 925.		
164.	MOORE, S. R. et al. "Production of Triglycerides Enriched in Long-Chain n-3 Polyunsaturated Fatty Acids from Fish Oil," <i>JAOCS</i> (1996), 73(11), 1409-1414.		
165.	NICOUD et al. <i>Proceedings of the 9<sup>th</sup> International Symposium on Preparative and Industrial Chromatography</i> , Société Française de Chimie April 1992, pp. 205-220.		
166.	NILSSON, W. B. "Supercritical fluid carbon dioxide fractionation of fish oil esters," <i>Adv. Seafood Chiochem., Pap. Am. Chem. Soc. Annu. Meet.</i> (1992), Meeting Date 1987, 151-168.		
167.	NORDØY, A. "Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease," <i>Minerva medica</i> (2002), 93(5), 357-363.		
168.	Omacor prescribing information from the FDA website: <a href="http://www.fda.gov/cder/foi/label/2004/216541bl.pdf">www.fda.gov/cder/foi/label/2004/216541bl.pdf</a> (9 pages).		
169.	Omacor prescribing information (1 page).		
170.	OMEGA-3-Acid Ethyl Esters 90, <i>European Pharmacopoeia</i> 5.3 (2006) 3571-3573.		
171.	OMEGA-3-Acid Ethyl Esters 60, <i>European Pharmacopoeia</i> 5.4 (2005) 3992-3997.		
172.	PERRY, R.H. et al., <i>Chemical Engineers Handbook</i> , 5th Edition, McGraw-Hill, New York, 1973, 13-55 and 13-56.		
173.	POWNALL, H. J. et al. "Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins," <i>Atherosclerosis</i> (1999), 143(2), 285-297.		
174.	Proceedings From the October 1987 Fish Oil Seminar, "Rendering Profits," (Alaska Fisheries Development Foundation, Inc. 1987) pp. 1-103.		
175.	Product specifications for EPAX 1050TG.		
176.	Product specifications for EPAX 4020EE.		
177.	Product specifications for EPAX 4020TG.		
178.	Product specifications for EPAX 4510TG.		
179.	Product specifications for EPAX 5500EE.		
180.	Product specifications for EPAX 6000EE.		
181.	Product specifications for EPAX 6000TG.		
182.	Product specifications for EPAX 6015EE.		
183.	Product specifications for EPAX 6015TG		
184.	REIS, G. J. et al. "Effects of Two Types of Fish Oil Supplements on Serum Lipids and Plasma Phospholipid Fatty Acids in Coronary Artery Disease," <i>Am. J. Cardiology</i> (1990), 66, 1171-1175.		
185.	SHIBATA, T. et al. "Effects of peroxisome proliferator-activated receptor-α and -γ agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats," <i>British J. of Pharmacol.</i> (2000), 130, 495-504.		
186.	SHIMADA, Y. et al. "Purification of Docosahexaenoic Acid by Selective Esterification of Fatty Acids from Tuna Oil with Rhizopus delemar Lipase," <i>JAOCS</i> (1997), 74(2), 97-101.		
187.	STALENHOEF, A. F. H. et al. "The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.D.C

IDS Form PTO/SB/08: Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/520,897		
		Filing Date	January 11, 2005		
		First Named Inventor	Sverre SONDBØ		
		Art Unit	1621		
		Examiner Name	Deborah D. Carr		
Sheet	7	of	7	Attorney Docket Number	10260.0007-00000

NONPATENT LITERATURE DOCUMENTS			
		lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia," <i>Atherosclerosis</i> (2000), 153(1), 129-138.	
	188.	TAKAGI, "Fractionation of Polyenoic Acids from Marine Lipids with Lipase," <i>Am. Oil Chem. Soc.</i> (1989), 66, 488-489.	
	189.	TANAKA, Y. et al. "Preparative separation of acylglycerol by centrifugal partition chromatography (CPC). II. Concentration of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) from lipase-hydrolyzed fish oil" <i>Yukagaku</i> (1992), 41(4), 312-316.	Abstract
	190.	Third Party Observation from corresponding European application no. 03764048.9-2108 dated September 26, 2006.	
	191.	TREYBAL, R.E., <i>Mass-Transfer Operations</i> , McGraw-Hill, New York, 1955, pp. 344-353.	
	192.	VAN DAM et al., "Efficacy of concentrated n-3 Fatty Acids in hypertriglyceridaemia - A Comparasion with Gemfibrozil:", <i>Clin. Drug Invest.</i> , pgs. 175-181, 2001.	
	193.	VERICEL, E. et al. "The influence of low intake of n-3 fatty acids on platelets in elderly people," <i>Atherosclerosis</i> (1999), 147(1), 187-192.	
	194.	XU, X. et al. "Purification and deodorization of structured lipids by short path distillation," <i>Eur. J. Lipid Sci. Technol.</i> (2002), 104, 745-755.	
	195.	Young, W. "Processing of oils and fats," <i>Chemistry and Industry</i> (1978), 16, 692-703.	
	196.	ZINGER et al. CA 106:118610 (1986).	
	197.	ZUYI, et al. "Stability of Microbial Lipase in Alcoholysis of Fish Oil During Repeated Enzyme Use," <i>Biotechnol. Lett.</i> (1993), 15(4), 393-398.	
	198.	ZUYI, et al. "Lipase-catalyzed alcoholysis to concentrate the n-3 polyunsaturated fatty acid of cod liver oil," <i>Enzyme Microb. Technol.</i> (1993), 15, 601-606.	

Examiner Signature	/Deborah D Carr/	Date Considered	02/04/2009
--------------------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.D.C